AIFF — Firefly Neuroscience Cashflow Statement
0.000.00%
Last trade - 00:00- $33.31m
- $30.57m
- $1.14m
Annual cashflow statement for Firefly Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.13 | -17.8 | -2.03 | -10.5 | -19.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.42 | 11.5 | -1.07 | 3.79 | 12.7 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.26 | -1.23 | 0.114 | 0.445 | -1.18 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.735 | -6.01 | -2.81 | -6.16 | -8.19 |
| Capital Expenditures | -0.07 | -0.536 | 0 | -0.415 | -0.128 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -9.51 | — | 2.34 | -0.062 | -2.36 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -9.58 | -0.536 | 2.34 | -0.477 | -2.49 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 13.4 | 2.35 | 0.43 | 6.3 | 11.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.07 | -4.2 | -0.049 | -0.333 | 0.937 |